# Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026

- Link: https://www.thailand-business-news.com/pr-news/rznomics-presents-clinical-interim-data-for-rz-001-in-recurrent-glioblastoma-at-asno-2026
- Published: 2026-06-15T11:00:00+07:00
- Author: PR Newswire

|   |

 ◦ **Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral
   presentation on interim data from 10 enrolled patients**
 ◦ **A manageable safety profile, with prolonged disease control and tumor recurrence
   inhibition observed in several patients**

SEONGNAM and SEOUL, South Korea, June 15, 2026 /PRNewswire/ — Rznomics Inc., a biopharmaceutical
company specializing in the development of RNA-based gene therapies, announced that
the Phase 1/2a interim clinical results for ‘RZ-001 (Taspitimagene advec)’, its 
RNA editing-based anticancer gene therapy for recurrent glioblastoma (rGBM), were
presented on June 13th at the Asian Society for Neuro-Oncology Annual Meeting (ASNO
2026) held in Kanazawa, Japan.

The presentation was delivered by Dr. Chae-Yong Kim, a professor of the Department
of Neurosurgery at Seoul National University Bundang Hospital, highlighting the 
safety and preliminary efficacy data from the ongoing clinical trial.

RZ-001 is an innovative anticancer gene therapy utilizing Rznomics’ proprietary 
RNA trans-splicing ribozyme platform, engineered to express a therapeutic gene specifically
inside tumor cells to induce cancer cell death. According to the presentation, 20
patients have completed screening to date, with 10 patients officially enrolled 
and treated in the trial.

The interim analysis revealed that no new or unexpected treatment-related safety
concerns have been identified. No dose-limiting toxicity (DLT) was reported, and
no treatment-related Grade 4 or higher adverse events were observed. Most reported
adverse events were deemed to be disease-related or associated with underlying conditions
typical of glioblastoma patients. Furthermore, several patients demonstrated prolonged
tumor recurrence inhibition and disease control exceeding six months.

Recurrent glioblastoma is one of the most aggressive and intractable malignant brain
tumors, notorious for high recurrence rates and an extremely poor prognosis even
after standard-of-care treatments. With currently approved treatment options showing
limited efficacy and conventional immuno-oncology therapies repeatedly facing clinical
failures, rGBM represents an area with immense unmet medical needs for novel therapeutic
mechanisms.

"The secured data demonstrate a manageable safety profile for RZ-001 alongside encouraging
preliminary signs of clinical activity," explained Dr. Chae-Yong Kim. "Given that
recurrent glioblastoma typically recurs within two to four months, the data from
patients showing long-term recurrence inhibition—particularly that of extending 
past nine months—is highly encouraging. We look forward to further clarifying its
full clinical value through additional patient enrollment and long-term follow-up
observations."

Meanwhile, RZ-001 is currently undergoing clinical development for both recurrent
glioblastoma and hepatocellular carcinoma (HCC). The HCC program recently achieved
a significant milestone by receiving Regenerative Medicine Advanced Therapy (RMAT)
designation from the U.S. FDA this past May.

**About Rznomics Inc.**
Rznomics is a clinical-stage biopharmaceutical company based
in South Korea focused on developing RNA-based gene therapies. The company’s proprietary
trans-splicing ribozyme platform enables precise RNA editing and has broad applicability
across multiple indications. The company signed a research collaboration and license
agreement with global pharmaceutical company Eli Lilly in May 2025 for the development
of a novel RNA editing therapeutic and listed on the KOSDAQ market in December 2025.(
KOSDAQ 476830)

For more information, please visit  [**www.rznomics.com**](https://www.rznomics.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026 ](http://www.prnasia.com/story/archive/4983263_CN83263_0?rand=184833)
